These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
436 related articles for article (PubMed ID: 1735081)
1. A chronopharmacologic phase II clinical trial with 5-fluorouracil, folinic acid, and oxaliplatin using an ambulatory multichannel programmable pump. High antitumor effectiveness against metastatic colorectal cancer. Lévi F; Misset JL; Brienza S; Adam R; Metzger G; Itzakhi M; Caussanel JP; Kunstlinger F; Lecouturier S; Descorps-Declère A Cancer; 1992 Feb; 69(4):893-900. PubMed ID: 1735081 [TBL] [Abstract][Full Text] [Related]
2. Chronomodulated versus fixed-infusion-rate delivery of ambulatory chemotherapy with oxaliplatin, fluorouracil, and folinic acid (leucovorin) in patients with colorectal cancer metastases: a randomized multi-institutional trial. Lévi FA; Zidani R; Vannetzel JM; Perpoint B; Focan C; Faggiuolo R; Chollet P; Garufi C; Itzhaki M; Dogliotti L J Natl Cancer Inst; 1994 Nov; 86(21):1608-17. PubMed ID: 7932825 [TBL] [Abstract][Full Text] [Related]
3. Biweekly intensified ambulatory chronomodulated chemotherapy with oxaliplatin, fluorouracil, and leucovorin in patients with metastatic colorectal cancer. Bertheault-Cvitkovic F; Jami A; Ithzaki M; Brummer PD; Brienza S; Adam R; Kunstlinger F; Bismuth H; Misset JL; Lévi F J Clin Oncol; 1996 Nov; 14(11):2950-8. PubMed ID: 8918492 [TBL] [Abstract][Full Text] [Related]
4. A multicenter evaluation of intensified, ambulatory, chronomodulated chemotherapy with oxaliplatin, 5-fluorouracil, and leucovorin as initial treatment of patients with metastatic colorectal carcinoma. International Organization for Cancer Chronotherapy. Lévi F; Zidani R; Brienza S; Dogliotti L; Perpoint B; Rotarski M; Letourneau Y; Llory JF; Chollet P; Le Rol A; Focan C Cancer; 1999 Jun; 85(12):2532-40. PubMed ID: 10375099 [TBL] [Abstract][Full Text] [Related]
5. Chronotherapy with 5-fluorouracil and folinic acid in advanced colorectal carcinoma. Results of a chronopharmacologic phase I trial. Adler S; Lang S; Langenmayer I; Eibl-Eibesfeldt B; Rump W; Emmerich B; Hallek M Cancer; 1994 Jun; 73(12):2905-12. PubMed ID: 8199987 [TBL] [Abstract][Full Text] [Related]
6. Bimonthly chemotherapy with oxaliplatin, irinotecan, infusional 5-fluorouracil/folinic acid in patients with metastatic colorectal cancer pretreated with irinotecan- or oxaliplatin-based chemotherapy. Nobili S; Checcacci D; Filippelli F; Del Buono S; Mazzocchi V; Mazzei T; Mini E J Chemother; 2008 Oct; 20(5):622-31. PubMed ID: 19028627 [TBL] [Abstract][Full Text] [Related]
7. Phase III multicenter randomized trial of oxaliplatin added to chronomodulated fluorouracil-leucovorin as first-line treatment of metastatic colorectal cancer. Giacchetti S; Perpoint B; Zidani R; Le Bail N; Faggiuolo R; Focan C; Chollet P; Llory JF; Letourneau Y; Coudert B; Bertheaut-Cvitkovic F; Larregain-Fournier D; Le Rol A; Walter S; Adam R; Misset JL; Lévi F J Clin Oncol; 2000 Jan; 18(1):136-47. PubMed ID: 10623704 [TBL] [Abstract][Full Text] [Related]
8. Whole-body hyperthermia (41.8 degrees C) combined with bimonthly oxaliplatin, high-dose leucovorin and 5-fluorouracil 48-hour continuous infusion in pretreated metastatic colorectal cancer: a phase II study. Hegewisch-Becker S; Gruber Y; Corovic A; Pichlmeier U; Atanackovic D; Nierhaus A; Hossfeld DK Ann Oncol; 2002 Aug; 13(8):1197-204. PubMed ID: 12181242 [TBL] [Abstract][Full Text] [Related]
9. Second-line chemotherapy with weekly oxaliplatin and high-dose 5-fluorouracil with folinic acid in metastatic colorectal carcinoma: a Hellenic Cooperative Oncology Group (HeCOG) phase II feasibility study. Janinis J; Papakostas P; Samelis G; Skarlos D; Papagianopoulos P; Fountzilas G Ann Oncol; 2000 Feb; 11(2):163-7. PubMed ID: 10761750 [TBL] [Abstract][Full Text] [Related]
10. Evaluation of oxaliplatin dose intensity in bimonthly leucovorin and 48-hour 5-fluorouracil continuous infusion regimens (FOLFOX) in pretreated metastatic colorectal cancer. Oncology Multidisciplinary Research Group (GERCOR). Maindrault-Goebel F; de Gramont A; Louvet C; André T; Carola E; Gilles V; Lotz JP; Tournigand C; Mabro M; Molitor JL; Artru P; Izrael V; Krulik M Ann Oncol; 2000 Nov; 11(11):1477-83. PubMed ID: 11142489 [TBL] [Abstract][Full Text] [Related]
11. Neoadjuvant treatment with weekly high-dose 5-fluorouracil as a 24h-infusion, folinic acid and biweekly oxaliplatin in patients with primary resectable liver metastases of colorectal cancer: long-term results of a phase II trial. Boxberger F; Albrecht H; Konturek PC; Reulbach U; Maennlein G; Meyer T; Hohenberger W; Hahn EG; Wein A Med Sci Monit; 2010 Feb; 16(2):CR49-55. PubMed ID: 20110914 [TBL] [Abstract][Full Text] [Related]
12. Multicenter phase II study of bimonthly high-dose leucovorin, fluorouracil infusion, and oxaliplatin for metastatic colorectal cancer resistant to the same leucovorin and fluorouracil regimen. André T; Bensmaine MA; Louvet C; François E; Lucas V; Desseigne F; Beerblock K; Bouché O; Carola E; Merrouche Y; Morvan F; Dupont-André G; de Gramont A J Clin Oncol; 1999 Nov; 17(11):3560-8. PubMed ID: 10550155 [TBL] [Abstract][Full Text] [Related]
13. Oxaliplatin and protracted continuous 5-fluorouracil infusion in patients with pretreated advanced colorectal carcinoma. Martoni A; Mini E; Pinto C; Nobili S; Gentile AL; Dentico P; Angelelli B; Scicolone S; Piana E; Mazzei T Ann Oncol; 2001 Apr; 12(4):519-24. PubMed ID: 11398887 [TBL] [Abstract][Full Text] [Related]
14. Palliative second-line treatment with weekly high-dose 5-fluorouracil as 24-hour infusion and folinic acid (AIO) plus oxaliplatin after pre-treatment with the AIO-regimen in colorectal cancer (CRC). Link K; Happich K; Schirner I; Jüngert B; Brückl V; Männlein G; Brückl WM; Merkel S; Göhl J; Hohenberger W; Hahn EG; Wein A Anticancer Res; 2004; 24(1):385-91. PubMed ID: 15015625 [TBL] [Abstract][Full Text] [Related]
15. Randomised multicentre trial of chronotherapy with oxaliplatin, fluorouracil, and folinic acid in metastatic colorectal cancer. International Organization for Cancer Chronotherapy. Lévi F; Zidani R; Misset JL Lancet; 1997 Sep; 350(9079):681-6. PubMed ID: 9291901 [TBL] [Abstract][Full Text] [Related]
16. The value of oxaliplatin in combination with continuous infusion +/- bolus 5-fluorouracil and levo-folinic acid in metastatic colorectal cancer progressing after 5FU-based chemotherapy: a GISCAD (Italian Group for the Study of Digestive Tract) cancer phase II trial. Mosconi S; Cascinu S; Zaniboni A; Catalano V; Giordani P; Beretta GD; Martignoni G; Pancera G; Baldelli AM; Poletti P; Curti C; Labianca R Tumori; 2000; 86(6):465-9. PubMed ID: 11218187 [TBL] [Abstract][Full Text] [Related]
17. Phase I study of a weekly schedule of oxaliplatin, high-dose leucovorin, and infusional fluorouracil in pretreated patients with advanced colorectal cancer. Rosati G; Rossi A; Tucci A; Pizza C; Manzione L Ann Oncol; 2001 May; 12(5):669-74. PubMed ID: 11432626 [TBL] [Abstract][Full Text] [Related]
18. A phase II study of irinotecan alternated with a weekly schedule of oxaliplatin, high-dose leucovorin and 48-hour infusion 5-fluorouracil in patients with advanced colorectal cancer. Rosati G; Tucci A; Rinaldi A; Colarusso D; Pizza C; Reggiardo G; Manzione L Oncology; 2004; 66(5):371-8. PubMed ID: 15331924 [TBL] [Abstract][Full Text] [Related]
19. Chronomodulated irinotecan, oxaliplatin, and leucovorin-modulated 5-Fluorouracil as ambulatory salvage therapy in patients with irinotecan- and oxaliplatin-resistant metastatic colorectal cancer. Gholam D; Giacchetti S; Brézault-Bonnet C; Bouchahda M; Hauteville D; Adam R; Ducot B; Ghémard O; Kustlinger F; Jasmin C; Lévi F Oncologist; 2006; 11(10):1072-80. PubMed ID: 17110626 [TBL] [Abstract][Full Text] [Related]
20. Triplet combination with irinotecan plus oxaliplatin plus continuous-infusion fluorouracil and leucovorin as first-line treatment in metastatic colorectal cancer: a multicenter phase II trial. Souglakos J; Mavroudis D; Kakolyris S; Kourousis Ch; Vardakis N; Androulakis N; Agelaki S; Kalbakis K; Tsetis D; Athanasiadis N; Samonis G; Georgoulias V J Clin Oncol; 2002 Jun; 20(11):2651-7. PubMed ID: 12039926 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]